Table 2

Treatment details for participants in each cohort

TrialMechanical thrombectomy cohortIV r-tPA cohort
TreatmentnAge
(±SD)
Median NIHSS
(IQR)
TreatmentnAge
(±SD)
Median NIHSS
(IQR)
MR CLEAN35±IV r-tPA + MT ± (IA r-tPA or intra-arterial urokinase)23365.8 (54.5–76)17 (14–21)±IV r-tPA26765.7 (55.5–76.4)18 (14–22)
REVASCAT36*±IV r-tPA + M.T.10365.7 (±11.3)17 (14–20)±IV r-tPA10367.2 (±9.5)17 (12–19)
EXTEND 1A37†IV r-tPA ± M.T.3568.6 (±12.3)17 (13–20)IV r-tPA3570.2 (±11.8)13 (9–19)
SWIFT-prime38†IV r-tPA ± M.T.9865.0 (±12.5)17 (13–20)IV r-tPA9866.3 (±11.3)17 (13–19)
ESCAPE39†M.T. ± IV r-tPA16571 (60–81)16 (13–20)±IV r-tPA15070 (60–81)17 (12–20)
THRACE40†IV r-tPA ± M.T.20066 (54–74)18 (15–21)IV r-tPA20268 (54–75)17 (13–20)
THERAPY41*IV r-tPA ± M.T.5567 (±11)17 (13–22)IV r-tPA5370 (±10)18 (14–22)
PISTE42IV r-tPA ± M.T.3367 (±17)18 (6–24)§IV r-tPA3264 (±16)14 (6–29)§
EASI43*IV r-tPA ± M.T.4074 (62.7–80)18 (13–21.75)IV r-tPA3771 (59–79)20 (12–23)
  • *Enrolment was halted early after positive results for thrombectomy were reported from other similar trials.

  • †Trial stopped early due to efficacy.

  • ‡Median (IQR).

  • §Median (±range).

  • ¶Mean (±SD).

  • IV r-tPA , intravenous recombinant tissue-type plasminogen activator; IA r-tPA, intra-arterial recombinant tissue-type plasminogen activator; MT, mechanical thrombectomy; NIHSS , National Institutes of Health Stroke Scale; IQR, interquartile range; SD, standard deviation